Rate My Professor Gregory Whiteley

Gregory Whiteley is an Adjunct Professor at the University of Newcastle, alongside adjunct appointments at the University of Sydney and Western Sydney University. Holding a PhD, he is the Executive Chairman of Whiteley Corporation, a Hunter region-based manufacturer specializing in infection prevention and control products. His academic and research career focuses on critical areas within public health and microbiology, including infection control, disinfectants and sterilants, biofilms, antimicrobial resistance, hospital hygiene, urinary tract infections, surface and instrument hygiene, dry surface biofilms, and biofilm-mediated infections.

Whiteley supervises extensive research projects in these domains and has authored numerous influential publications, such as 'Severe chronic UTI sustained by clinically undetected intracellular Escherichia coli in a pediatric patient' (2025), 'Combating biofilm formation and bacterial killing: N-acetylcysteine’s efficacy against Pseudomonas aeruginosa in urinary catheters' (2025), 'Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review' (2024), 'Biofilm Mediated Infections, Antimicrobial Resistance and the challenge of interventional treatments' (2023), and 'Transmission of Staphylococcus aureus from dry surface biofilm (DSB) via different types of gloves' (2018). His scholarship is evidenced by over 1,300 citations on Google Scholar. He leads major initiatives, including the $5.6 million Cooperative Research Centre Project on chronic wound management in partnership with the University of Newcastle, Western Sydney University, Genesys Electronics Design, and Ampcontrol. Whiteley has served on Australian Standards committees, consults for the Australian Dental Association's National Infection Control Committee, and participates in industry boards across Australia and the United States, shaping global standards in infection prevention.